Novelix Pharmaceuticals Director Designation Change

Scrip Id

NOVELIX

Novelix Pharmaceuticals Limited submitted a regulatory disclosure to BSE Limited regarding a change in director designation. The Board of Directors in their meeting held on 11th November, 2026 approved the change in designation of Mr. Venkateshwarlu Pulluru from Whole-time Director to Non-Executive Non-Independent Director of the Company effective from the closing of business hours on 11th November, 2026.

Consequent to this change, Mr. Venkateshwarlu Pulluru ceased to hold the position of Whole-Time Director but continues as a Non-Executive Non-Independent Director of the Company, liable to retire by rotation in accordance with the Companies Act, 2013. The change in designation does not affect the continuity of his directorship on the Board.

The board meeting commenced at 05:00 PM and concluded at 05:43 PM on 11th November, 2026.

The disclosure was made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Annexure I Details

Reason for change: Based on the letter received from Mr. Venkateshwarlu Pulluru, the Board approved the change in designation from Whole time Director to Non-Executive Non-Independent Director.

Effective Date: 11th November, 2026

Brief profile: Not Available (NA)

Disclosure of Relationship between Directors: Nil

Director's Request Letter

Mr. Venkateshwarlu Pulluru submitted a written request to the Board dated 11th November, 2026 requesting redesignation from Whole-Time Director to Non-Executive Director effective from the close of business hours on 11th November, 2026. The request was made due to personal and professional commitments, with the director wishing to relinquish executive responsibilities while continuing to serve as a Non-Executive Director subject to applicable provisions of the Companies Act, 2013.

The letter was digitally signed by Gattu Gnana Prakash, Whole-time director (DIN: 00517921) on behalf of Novelix Pharmaceuticals Limited.